IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with CryoProbes. The XSense system, which is designed for general minimally invasive cryoablation, received FDA clearance for all the approved indications for IceCure’s other cryoablation system, ProSense, including general minimally invasive cryoablation in the fields of general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery, ENT, gynecology, oncology, proctology and urology. Significance of the Announcement The FDA clearance is based on the safety and efficacy data of IceCure’s cryoablation platform. The platform offers a cutting-edge alternative to traditional surgical tumor removal by destroying tumors through freezing. The system uses liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung and liver. Per IceCure Medical, the FDA approval for the XSense Cryoablation System marks a significant step in the medical technology landscape. Following the FDA clearance, IceCure is likely to solidify its position as a global leader in cryoablation solutions, providing multiple minimally invasive options that can potentially transform patient care across several illnesses like fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions and warts. The XSense system, building on the success of the ProSense system, is set to address unmet medical needs with its versatility and effectiveness in treating various tissues and tumors. This development is anticipated to benefit patients by offering less invasive treatment options, physicians by expanding therapeutic tools, and healthcare payors by potentially reducing overall treatment costs. More on the News IceCure's cryoablation systems enhance value for patients and providers by accelerating recovery and reducing pain, surgical risks and complications. Their easy, transportable design and liquid nitrogen utilization enable ProSense and XSense collaboration to facilitate fast and convenient office-based procedures for breast tumors. The company’s De Novo Classification Request for marketing clearance of the ProSense Cryoablation System for the treatment of patients with early-stage, low-risk breast cancer is under review with the FDA. An advisory panel is expected to be convened in the fourth quarter of 2024 to discuss the request, with a potential decision on FDA approval in early 2025. Industry Prospects Per a report by Global Market Insights, the global cryoablation market size was worth $691 million in 2022. It is anticipated to reach $1.6 billion in 2032 at a CAGR of 8.5% Continuous advancements in cryoablation devices will act as a significant factor in accelerating market penetration. Developing and launching advanced technology with inbuilt devices that offer better device performance, accuracy and safety will boost the demand for cryoablation devices. Furthermore, several manufacturers are producing devices with superior cooling processes, enhanced imaging capabilities and improved catheter designs for precise and efficient tissue targeting, which will propel market growth. Recent Developments In April, IceCure announced the submission of final data from the ICE3 study to the FDA to support its marketing authorization request for the use of ProSense in early-stage breast cancer. The ICE3 study data demonstrated that 96.3% of early-stage breast cancer patients treated with ProSense cryoablation followed by hormone therapy were free from local recurrence at five years. This outcome is comparable to a 97.7% recurrence-free rate from other breast cancer studies — the LUMINA study (evaluating breast-conserving surgery) and the 97.19% rate from the PRISMA meta-study (evaluating radiotherapy). ICE3 results align with real-world data from territories using ProSense. No significant device-related adverse events or complications were reported, with high satisfaction among patients and physicians. Price Performance Shares of IceCure Medical have declined 30.7% so far this year against the industry's 3.6% rise. The S&P 500 has witnessed a 15% rise in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Other Key Picks Currently, IceCure Medical carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are DaVita Inc. DVA, Universal Health Services UHS and Ecolab Inc. ECL. DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 43.4% compared with the industry’s 15.2% rise in the past year. Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.80%. UHS’s earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%. Universal Health Services has gained 21.3% against the industry’s 20.4% decline in the past year. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%. Ecolab’s shares have rallied 31.3% against the industry’s 12.9% decline in the past year Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report IceCure Medical Ltd. (ICCM):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...